Revelation BiosciencesREVB
13F holders, Q1 2026 (March 31)11holders +10
9new positions
0sold out
$1.20avg. 13F price*
At the end of Q1 2026, 11 institutions reported holding Revelation Biosciences Inc. (REVB) in their 13F filings, up 10 from Q4 2025. 9 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($388K), Sabby Management, LLC ($119K) and Geode Capital Management, LLC ($52K).
- Company
- Revelation Biosciences Inc.
- CUSIP
- 76135L804
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $584K |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 486,199 shares bought and 114 shares sold, net +486,085 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Armistice Capital, LLC | 0.01% | New | 323,241 | $388K |
| Sabby Management, LLC | 2.26% | New | 99,432 | $119K |
| Geode Capital Management, LLC | 0.00% | New | 43,195 | $52K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 13,127 | $16K |
| XTX Topco Ltd | 0.00% | New | 11,385 | $14K |
| UBS Group AG | 0.00% | New | 4,115 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 4,074 | $5K |
| Royal Bank of Canada | 0.00% | New | 747 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -24.9% | 344 | $413 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | New | 9 | $11 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is REVB's weight in each manager's 13F, not the share of Revelation Biosciences Inc. the manager owns.